JPET # 139386

INTRODUCTION
The ritalinic acid psychostimulant, methylphenidate (MPD), is frequently used to treat attention-deficit hyperactivity disorder. It is well established that MPD prevents the clearance of dopamine (DA) from the synaptic cleft by binding to the neuronal DA transporter (DAT) (Wayment et al., 1999; Volz et al., 2005; Volz and Schenk, 2005) . In addition, MPD also indirectly affects the vesicular monoamine transporter-2 (VMAT-2); a protein that sequesters cytoplasmic DA inside the synaptic vesicles of nerve terminals. A single MPD treatment increases DA transport, VMAT-2 immunoreactivity, and binding of the VMAT-2 ligand,
[
3 H]dihydrotetrabenazine, in cytoplasmic vesicles purified from osmotic lysates of rat striatal synaptosomes (Sandoval et al., 2002; Sandoval et al., 2003; Volz et al., 2007a) . These effects on cytoplasmic vesicles are D2 receptor-mediated, as the D2 receptor antagonist, eticlopride (ETIC), attenuates or blocks these effects and the D2 receptor agonist, quinpirole (QUIN), mimics the effects of MPD (Sandoval et al., 2002; Truong et al., 2004) .
In contrast to studies described above involving cytoplasmic vesicles, a recent study (Volz et al., 2007a) characterized the largely undescribed population of membrane-associated VMAT-2-containing vesicles that co-fractionate with striatal synaptosomal membranes after osmotic lysis. Strikingly and in contrast to cytoplasmic vesicles, DA transport into these membrane-associated vesicles is cooperative with a sigmoidal response curve and has a large DA sequestration capacity at elevated concentrations of DA (Volz et al., 2007a) . As predicted from studies involving cytoplasmic vesicles, MPD administration decreases VMAT-2 immunoreactivity in this membrane-associated vesicle fraction. Unexpectedly, MPD also kinetically upregulates DA transport in vesicles remaining in the membrane-associated fraction after MPD-induced trafficking such that these vesicles sequester a larger quantity of DA due to This article has not been copyedited and formatted. The final version may differ from this version.
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While the impact of D2 receptors on cytoplasmic vesicles has been reported (Sandoval et al., 2002; Truong et al., 2004) , the receptor-mediated mechanisms underlying the effects of MPD on membrane-associated vesicle function have not been described. Accordingly, this report presents new information elucidating the receptor-mediated mechanisms responsible for the effects of MPD on this important membrane-associated vesicle population using ETIC and QUIN and also describes the functional consequences of these effects. Owing to the affinity of MPD for muscarinic receptors (Markowitz et al., 2006) , the effects of the muscarinic receptor antagonist, scopolamine (SCOP), and the muscarinic receptor agonist, oxotremorine (OXO), on DA release were also examined. In addition, because the anatomical localization of muscarinic receptors suggests the possibility that muscarinic receptors may influence glutamatergic function (Hersch et al., 1994) and high concentrations of glutamate can increase striatal DA release (Moghaddam et al., 1990) , the effects of the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801 ((5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine), were also studied. The results demonstrate the new findings that D2 receptor activation mediates the MPD-induced upregulation of DA transport in vesicles remaining at the membrane and a MPDinduced increase in striatal DA release. Muscarinic, but not NMDA, receptor activation is also required for MPD to affect the actual DA release process. These findings provide novel insights into the receptor-mediated mechanism of action of MPD in the striatum as well as the physiological regulation of vesicular DA sequestration and synaptic transmission. Accordingly, these data may advance the treatment of disorders involving abnormal DA disposition including
Parkinson's disease, attention-deficit hyperactivity disorder, and substance abuse.
This article has not been copyedited and formatted. The final version may differ from this version. were administered at doses previously used to investigate receptor-mediated effects in rat brain (Hernandez-Lopez et al., 1992; Keefe and Adams, 1998; Casas et al., 1999; Forster and Blaha, 2000; Ichikawa et al., 2002; Sandoval et al., 2002; Kilbourn et al., 2004; Truong et al., 2004; Riddle et al., 2007; Volz et al., 2007a) . Drug doses were calculated as the free base and were dissolved in 0.9 % (w/v) saline before being administered at 1 ml/kg as indicated in the figure legends.
The pH 7.4 sucrose buffer contained 320 mM sucrose, 3.8 mM NaH 2 PO 4 , and 12.7 mM Na 2 HPO 4 . The pH 7.5 VMAT-2 assay buffer consisted of 25 mM HEPES, 100 mM potassium tartrate, 0.05 mM EGTA, 0.1 mM EDTA, and 2 mM ATP-Mg
+2
. The pH 7.4 DAT assay buffer consisted of 126 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl 2 , 16 mM sodium phosphate, 1.4 mM MgSO 4 , and 11 mM dextrose. The pH 2.5 tissue buffer consisted of 50 mM sodium phosphate, 30 mM citric acid, and 10 % (v/v) methanol.
This article has not been copyedited and formatted. The final version may differ from this version. (Schenk et al., 2005; Volz et al., 2006 ) was used to measure the initial velocities of inwardly directed vesicular DA transport into membraneassociated vesicles purified from rat striata as described previously (Volz et al., 2007a) . Each sample consisted of both striata (~ 60-70 mg total wet weight) from a rat that were homogenized Bradford protein assay.
VMAT-2 Immunoreactivity
After RDE measurement of DA transport velocities, SDS-polyacrylamide gel electrophoresis and Western blot analysis were performed on the membrane-associated vesicle samples as previously described Volz et al., 2007a) . (Maidstone, England) Partisphere C18 column) that was coupled to an electrochemical detector (+ 730 mV relative to a Ag/AgCl reference electrode). The pH 2.86 mobile phase consisted of 50 mM sodium phosphate, 30 mM citric acid, 0.16 mM EDTA, 1.5 mM sodium octyl sulfate, and 10 % (v/v) methanol (Chapin et al., 1986) .
Measurement of K + -stimulated DA Release RDE voltammetry (Schenk et al., 2005; Volz et al., 2006 ) was used to measure K + -stimulated DA release in striatal suspensions prepared from treated rats as previously described (McElvain and Schenk, 1992; Volz et al., 2007a) . Each sample consisted of one striatum (~ 28-38 mg wet weight) that was placed on an ice-cold watch glass and chopped by hand with an iceThis article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Experiments were initially conducted to investigate the D2 receptor-mediated effects of MPD on membrane-associated vesicles. In these studies, it is important to note that the plasmalemmal DAT does not contribute to measurable DA binding or transport in the membrane-associated vesicle subcellular fraction (Volz et al., 2007a) . The results presented in In striking contrast to the D2 receptor-mediated ability of MPD to increase DA release, QUIN administration (1 mg/kg, i.p.) decreased both the velocity and magnitude of K + -stimulated DA release from striatal suspensions (Fig. 6) . QUIN (1 mg/kg, i.p.) did not affect the duration of K + -stimulated DA release (5 + 1 s for saline and 5.4 + 0.2 s for QUIN; N = 4). Given this apparent disparity between these D2 receptor-mediated effects on DA release and numerous reports demonstrating that D2 receptor activation decreases K + -stimulated striatal DA release (Starke et al., 1989; Pothos et al., 1998) , additional experiments were conducted to determine the mechanism underlying the effects of MPD on DA release. MPD has affinity for muscarinic receptors (Markowitz et al., 2006) (Riddle et al., 2007) ) to increase the velocity (Fig. 8A) and magnitude (Fig. 8B) Finally, because the anatomical localization of muscarinic receptors suggests the possibility that muscarinic receptors may influence glutamatergic function (Hersch et al., 1994) and high concentrations of glutamate can increase striatal DA release (Moghaddam et al., 1990) , 
DISCUSSION
The present study confirms and extends previous findings involving cytoplasmic vesicles (Sandoval et al., 2002; Truong et al., 2004 ) that D2 receptors mediate the ability of MPD to traffic synaptosomal membrane-associated synaptic vesicles from membranes into the cytoplasm as ETIC blocks the MPD-induced decreases in membrane-associated VMAT-2 immunoreactivity (Fig. 1) . ETIC also prevents the MPD-induced increase in vesicular DA transport. Like MPD, QUIN increases DA transport and decreases VMAT-2 immunoreactivity in the membraneassociated vesicle fraction, and these effects are blocked by ETIC (Fig. 2) . Taken together, these data suggest that both the MPD-induced trafficking of vesicles out of the membrane-associated fraction and the MPD-induced kinetic upregulation of VMAT-2 in the remaining membraneassociated vesicles are D2 receptor-mediated. However, it should also be noted that QUIN also has some affinity for D3 receptors (Moreland et al., 2004) . Because MPD has no significant binding affinity for DA receptors (Markowitz et al., 2006) , these effects are likely due to MPDinduced increases in extracellular DA concentrations caused by DAT blockade rather than to a direct interaction between MPD and D2 receptors.
The MPD-induced increases in vesicular DA transport (due to vesicle trafficking in cytoplasmic vesicles and kinetic upregulation of VMAT-2 in membrane-associated vesicles (Volz et al., 2007a) ) result in an increase in the DA content of the cytoplasmic and membraneassociated vesicle fractions (Fig. 3) . Because MPD administration does not change whole striatal tissue DA content (Sandoval et al., 2003) , this likely represents a redistribution of DA within the striatum from the cytoplasm and into the vesicles. Consistent with the above finding that D2 receptors mediate both trafficking and kinetic upregulation, QUIN also increases cytoplasmic and membrane-associated vesicular DA content (Fig. 4) .
This article has not been copyedited and formatted. The final version may differ from this version. (Sandoval et al., 2003) . The MPD-induced redistribution of DA within the striatum from the cytoplasm into the vesicles may attenuate methamphetamine-induced aberrant cytoplasmic DA accumulation and the subsequent formation of DA-associated reactive oxygen species (Volz et al., 2007b; Volz et al., 2007c) which cause persistent dopaminergic deficits (Cubells et al., 1994; Cadet and Brannock, 1998; Fumagalli et al., 1999) . Because abnormal cytoplasmic DA accumulation may also contribute to the development of Parkinson's disease (Jenner, 1998) , the potential of MPD-induced increases in vesicular DA sequestration to attenuate the disease's progression merits further investigation; as suggested by findings that MPD treatment improves motor function in Parkinson's patients (Devos et al., 2007) .
Another predictable functional consequence of a MPD-induced increase in the DA content of cytoplasmic and membrane-associated vesicles is an increase in both the velocity and magnitude of K + -stimulated DA release from striatal suspensions (Volz et al., 2007a) . This is of particular interest, as both the speed of neurotransmitter release and the amount of vesicular DA content can influence receptor activation (Liu, 2003; Edwards, 2007) , and thus MPD treatment may influence quantal synaptic transmission in the striatum by increasing the rate at which DA receptors are exposed to DA, and perhaps the magnitude and/or duration of this effect. D2
receptor activation mediates these increases, as ETIC blocks both the MPD-induced increases in velocity ( Fig. 5A ) and magnitude ( Fig. 5B) (Starke et al., 1989; Pothos et al., 1998) , as well as the present findings that QUIN decreases both the velocity and magnitude of K + -stimulated DA release from striatal suspensions (Fig. 6) . These results suggest that while D2
receptors mediate the effects of MPD on vesicle trafficking, vesicular DA transport, and vesicular DA content, D2 receptors do not wholly and completely mediate the effects of MPD on K + -stimulated DA release. Thus, investigations were conducted to determine if additional mechanisms contribute to the MPD-induced increases in K + -stimulated DA release.
Muscarinic receptors were selected for study because MPD has significant affinity for these receptors (see Results). A potential role for muscarinic receptors in mediating the effects of MPD on DA release was suggested by findings that, like MPD, the muscarinic receptor agonist, OXO, increases K + -stimulated DA release in rat striatum (Raiteri et al., 1984) . This potential was confirmed by findings that OXO mimicked the effects of MPD by increasing both the velocity (Fig. 7A ) and magnitude ( Fig. 7B ) of K + -stimulated DA release from striatal suspensions. Accordingly, experiments were conducted to determine whether antagonism of muscarinic receptors could block the effects of MPD on DA release in the striatum.
SCOP (administered at a commonly used dose of 5 mg/kg (Hernandez-Lopez et al., 1992; Casas et al., 1999; Forster and Blaha, 2000; Kilbourn et al., 2004) ) did not alter MPD-induced increases in K + -stimulated DA release following administration of a high dose (40 mg/kg) of MPD (i.e., the dose selected for study previously when characterizing mechanisms affecting cytoplasmic vesicles (Sandoval et al., 2002; Volz et al., 2007a) ). However, SCOP completely blocked the effects of a lower dose (2 mg/kg) of MPD on K + -stimulated DA release velocity ( 8A) and DA release magnitude (Fig. 8B) . It is noteworthy that the lower MPD dose traffics synaptic vesicles (Riddle et al., 2007) and increases the velocity (Fig. 8A) and magnitude ( Fig.   8B ) of DA release as does the 40 mg/kg dose of MPD , and thus it is likely that both doses elicit the same phenomenon. The inability of SCOP to attenuate the effects of the higher MPD dose may be due to an inability to adequately compete for muscarinic receptor binding sites.
Alternatively, non-muscarinic mechanisms may be initiated by the higher dose of MPD that, like muscarinic receptor activation, increase DA release. This latter possibility remains to be tested.
The muscarinic effect on DA release may be indirect and one possible mechanism involves muscarinic receptors controlling glutamate release. The anatomical localization of muscarinic receptors suggests the possibility that muscarinic receptors may influence glutamatergic function (Hersch et al., 1994) . Further high concentrations of glutamate can increase striatal DA release (Moghaddam et al., 1990) . However, MK-801 pretreatment did not alter the effects of MPD on K + -stimulated DA release nor did it have any effect on DA release on its own (Fig. 9 ). This suggests that NMDA receptors do not mediate the increase in DA release seen after MPD which would indicate that changes in NMDA receptor-mediated glutamatergic signaling are not the intermediate step between muscarinic receptor activation and increases in DA release.
In summary, the present results elucidate a heretofore-unreported mechanism whereby MPD alters striatal DA transmission. D2 receptors mediate the ability of MPD to: 1) traffic vesicles away from synaptosomal membranes and into the cytoplasm which increases DA transport into cytoplasmic vesicles; and 2) kinetically upregulate VMAT-2 in vesicles that remain associated with synaptosomal membranes such that DA transport into the membraneassociated vesicles is increased as well. This results in a redistribution of DA within the striatum 
